| 120px|Merck KGaA's logo 90px|EMD logo | |
| Company type | Publicly traded Aktieselskab (Nasdaq Copenhagen: ALK B) |
|---|---|
| Industry | pharmaceuticals |
| Founded | 1668 |
| Founder | Friedrich Jacob Merck |
| Headquarters | , |
Key people | Jens Bager(President and CEO), Jørgen Worning (Chairman of the supervisory board) |
| Products | Epipens, life science and performance chemicals, over-the-counter medicines, small molecules and biopharmaceuticals |
| Revenue | DKK1.935 billion (2009)[1] |
| DKK175 million (2009)[1] | |
| DKK118 million (2009)[1] | |
Number of employees | 1,700 30 September 2010[2] |
| Subsidiaries | Merck Serono |
| Website | www.alk-abello.com |
ALK-Abelló (Nasdaq Copenhagen: ALK B) is a Denmark-based pharmaceutical company producing vaccines for allergy and asthma.
External links edit
- http://www.alk-abello.com/ - Company Homepage.
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
Danish developer of diagnostic tools and treatments for allergys. Makes EpiPen for emergency treatment of allergic reactions to food or insect venom. Peers are Stallergenes, Genmab and Affitech. Partnered with Merck & Co in the US. Spun out of Christian Hansen in 2005.
main development product is hayfever treatment Grazax
http://www.alk-lifeline.co.uk/pages/faqs.aspx
- ^ a b c "Annual Report 2009" (PDF). Merck. Retrieved 2010-03-13.
- ^ Merck KGaA: Quartals-Finanzbericht 2010. dated 26 Oktober 2010